The more they’ve spent, the less they’ll say.
Peptides are what every serious player is building for. Talk about them, and money spent on them, run in opposite directions.
Sai Life says “peptide” twenty-eight times and has committed, on its own estimate, “probably less than ₹300 crores” through 2028. Neuland says it nineteen times and says “GLP-1” not once — while spending ₹121.6 crore in one quarter inside ₹1,460 crore approved.
Divi’s, with about ₹2,000 crore committed, was asked directly whether the quarter contained GLP-1 supply:
“See, I cannot answer that question if you ask me about GLP-1s or small molecules.” Dr Kiran S. Divi, CEO · Divi’s Laboratories · 1 August 2026
Laurus, on semaglutide: “we are not able to discuss any project-specific details.” Piramal and Syngene did not use the word once — and have the two worst returns on capital in the group.
A sector, read end to end, and the companies as they are published. Roughly monthly. Nothing else, and one click to stop.
Not advice. Quotes are from the companies’ own earnings calls; figures from their filings.